Boucher Kelley 4

What Happened
Kelley Boucher, Chief People Officer of Apellis Pharmaceuticals (APLS), was granted 30,146 restricted stock units (RSUs) on January 28, 2026. The grant is reported as an acquisition at $0.00 per share (total reported acquisition value $0), which reflects a non‑cash RSU award rather than an open‑market purchase.

Key Details

• Transaction date: January 28, 2026 (reported on Form 4 filed January 30, 2026).
• Transaction type/code: Grant / Award (A).
• Units granted: 30,146 RSUs.
• Reported price: $0.00 per share; acquisition value reported as $0.
• Vesting: 25% annually over four years from the grant date, subject to continued service (footnote F1).
• Shares owned after transaction: Not specified in the provided filing summary.
• Timeliness: Form 4 filed two days after the grant date (appears to be timely under SEC rules).

Context
RSUs represent a deferred equity award that converts into shares upon vesting and do not indicate an immediate cash outlay or market purchase. Such grants are common executive compensation/retention tools and should be viewed as compensation rather than a direct bullish or bearish trading signal. No 10b5‑1 plan, tax‑withholding details, or late‑filing flags were noted in the provided information.